Get the latest public health information from CDC: https://www.coronavirus.gov
Get the latest research information from NIH: https://www.nih.gov/coronavirus
NIH staff guidance on coronavirus (NIH Only)
The Epilepsy Research Benchmarks reflect priorities shared across the epilepsy community for research toward clinically meaningful advances in understanding and treating the epilepsies. Since their initial development in 2000, the Benchmarks have brought attention to goals such as developing new animal models of the epilepsies, identifying the genes underlying the genetic epilepsies, preventing epileptogenesis, addressing aspects of epilepsy beyond seizures, and confronting the challenge of sudden unexpected death in epilepsy (SUDEP) and mortality associated with epilepsy.
The Epilepsy Benchmark Stewards Committee, coordinated by the American Epilepsy Society, has developed a draft of the 2020 Epilepsy Research Benchmarks as a framework for focusing research and benchmarking progress over the next five to ten years. The final 2020 Benchmarks will incorporate revisions in response to public comments gathered through a Request for Information (RFI), through the use of a crowdsourcing exercise, and finally at the conference to be held in January 2021. Please join the community in providing your ideas, comments and feedback on the 2020 Epilepsy Research Benchmarks by logging into Ideascale.
The four working groups of the Epilepsy Benchmark Stewards Committee provided progress updates in these publications:
The Epilepsy Benchmark Stewards Committee also produced these videos summarizing the draft 2020 Epilepsy Research Benchmarks:
Area I. Understand the causes of the epilepsies and their relationship to epilepsy-associated neurologic, psychiatric, and somatic conditions.
Area II. Prevent epilepsy and its progression.
Area III. Improve treatment options for controlling seizures and epilepsy-related conditions while limiting side effects.
Area IV. Limit, treat, or prevent co-occurring conditions associated with epilepsy across the lifespan in general and special epilepsy populations.
Learn More: